Elsevier and eMolecules Collaboration Enables Easy Sourcing of Chemicals via Reaxys(R)

September 14, 2010

FRANKFURT, September 14, 2010 /PRNewswire/ –

– Enriched Content Offering Integrates Reaction and Substance Searching,
Synthesis Planning and Chemical Procurement Into a Seamless Workflow

Elsevier is pleased to announce that Reaxys now provides an enriched
commercial availability service, as a result of the ongoing collaboration
between the Reaxys development team and eMolecules. Chemical procurement of
commercially available compounds is now incorporated into the reaction and
substance search workflow. Research chemists can now immediately access the
eMolecules ordering page, complete with full quantity, pricing and vendor
information, all via the eMolecules icon. It becomes part of the overall
research workflow, the chemist can order the desired compound and easily
continue with their reaction or substance query.

Reaxys is Elsevier’s web-based chemistry application which combines
reaction and substance data search and retrieval in organic, organometallic,
inorganic and physical chemistry with synthesis planning. Reaxys allows
research chemists to get important and relevant information from journals and
patents fast and conveniently in a single overview.

Mark van Mierle, MD of Elsevier Information Systems, said, “Sourcing the
right chemical at the best price and in an easy manner is clearly a crucial
step in a chemist’s workflow. I believe this enhancement to Reaxys will
enable chemists to make better decisions and get back to the lab more

Klaus Gubernator, CEO, eMolecules, added, “The collaboration between
Elsevier and eMolecules focuses on providing our customers with an enhanced
user experience, and the incorporation of all elements of the chemist’s
workflow into one integrated system.”

The Reaxys development team will continue to work with eMolecules to
further streamline all aspects of the commercial availability process in
order to bring the researchers the most relevant information with fewer

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (http://www.thelancet.com) and Cell
(http://www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier’s online solutions include
ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com),
Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and
Nursing Consult (http://www.nursingconsult.com), which enhance the
productivity of science and health professionals, and the SciVal suite
(http://www.scival.com) and MEDai’s Pinpoint Review (http://www.medai.com),
which help research and health care institutions deliver better outcomes more

A global business headquartered in Amsterdam, Elsevier
(http://www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About eMolecules

eMolecules is the world’s leading open-access chemical structure search
engine, providing chemistry eCommerce solutions for suppliers of research
chemicals and industrial and academic research organizations. They deliver
chemical building blocks and screening compounds worldwide from any supplier
in any requested physical format. They are the most popular chemistry web
site, distinguished by fast results, ease of use, and up to date information
about commercially available chemicals.

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed Elsevier for
the management of intellectual property. Elsevier Properties SA owns the
PharmaPendium, Beilstein and Reaxys databases. Trademarks including
Reaxys(R), PharmaPendium(TM), SciVal(TM) and The Lancet(R) are owned and
protected by Elsevier Properties SA and used under license. For additional
information see http://www.reedelsevier.com.

    Media Contact
    Tom Reller
    Vice President, Global Corporate Relations

SOURCE Elsevier and Elsevier Properties

Source: newswire

comments powered by Disqus